Arthur A. Torres - 14 May 2026 Form 4 Insider Report for CareDx, Inc. (CDNA)

Reporting relationship: Director
Issuer ticker: CDNA
Reported as of: 14 May 2026
Net transaction value: -$214,676
SEC form: 4
Accepted by SEC: 18 May 2026, 16:05:10 UTC
Prior SEC filing: 17 Jun 2025
Source filing: View source filing
Reporting owner signature: /s/ Jeffrey Adam Novack

Key filing fact

Arthur A. Torres filed Form 4 for CareDx, Inc. (CDNA) on 18 May 2026.

Key facts

This page summarizes Arthur A. Torres's Form 4 filing for CareDx, Inc. (CDNA).
2 reported transactions and 0 derivative rows are listed below.
Accepted by SEC: 18 May 2026, 16:05.

Change

Previous filing in this sequence was filed on 17 Jun 2025.
Current net transaction value: -$214,676.

Research use

This tells you what this filing adds before you inspect full transaction and derivative tables.
You can trace every row back to the original SEC filing document.

Evidence

Filed on Form 4

Ownership activity is grounded in SEC Form 4 disclosures.

View source filing

Reporting Owners (1)

CIK 0001251737 Primary reporting owner

TORRES ARTHUR A

Relationship: Director
Address: C/O CAREDX, INC., 8000 MARINA BOULEVARD, 4TH FLOOR, BRISBANE
Signature: /s/ Jeffrey Adam Novack
Signature date: 18 May 2026

Reported non-derivative transactions

Shares, units, or other non-derivative securities reported in this filing.

CDNA transaction

Common Stock

Sale

Transaction value: $85,698
Shares: -4,086
Change %: -8.3%
Price: $20.97
Shares after: 45,149
Date: 14 May 2026
Ownership: Direct
Footnotes: F1

CDNA transaction

Common Stock

Sale

Transaction value: $128,978
Shares: -6,484
Change %: -14%
Price: $19.89
Shares after: 38,665
Date: 15 May 2026
Ownership: Direct
Footnotes: F2

^* marks a reported price that did not pass the local price check.

Additional SEC filing notes

Filing notes and footnotes

Explanation of responses 2 footnotes

Footnote F1

The reported price in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $20.96 to $21.03 per share, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.

Footnote F2

The reported price in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $19.73 to $20.105 per share, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.